Latest News | Lupin Receives USFDA Nod for Generic Drug
Get latest articles and stories on Latest News at LatestLY. Pharma company Lupin on Monday said it has received approval from the US health regulator to market a generic drug used in the treatment of seizures associated with Lennox-Gastaut syndrome.
New Delhi, Dec 21 (PTI) Pharma company Lupin on Monday said it has received approval from the US health regulator to market a generic drug used in the treatment of seizures associated with Lennox-Gastaut syndrome.
The company has received approval from the US Food and Drug Administration (USFDA)for its Rufinamide Oral Suspension in 40 mg/mL strength, Lupin said in a statement.
The drug maker's product is the generic equivalent of Eisai Inc's Banzel oral suspension.
Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients of one year of age and older, and in adults.
As per IQVIA MAT September 2020 data, the product had annual sales of around USD 124.5 million in the US market.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)